JAZZ vs ARXS Comparison

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Arxis Inc designs and manufactures proprietary electronic and mechanical components used in applications that require performance in extreme environments. The company operates in two reportable segments: i) Electronic Components: It provides specialized, engineered electronic components and interconnect solutions, including connectors, cable assemblies, microelectronic packaging, RF and microwave products, power products, sensors, capacitors and resistors. and ii) Mechanical Components: It provides precision and self-lubricating bearings, seals, springs, gaskets and ducting, and radar absorbing materials. The majority of the company's revenue is derived from the Mechanical Components segment. Geographically, it generates the maximum revenue from the United States.